In contrast to the previous KRAS mechanism34, MYC inhibition did not alter UPP1 expression or appear among the transcription factors binding to the UPP1 promoter (Extended Data Fig. 9a–c), suggesting that MYC does not mediate KRAS regulation of UPP1 in PDA. The gene discussed is KRAS; the disease is Patent ductus arteriosus.